Rigontec Appoints Dr. Jörg Vollmer as Chief Scientific Officer
in portfolio news
Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced that Dr. Jörg Vollmer has joined the Company as Chief Scientific Officer. Dr. Vollmer brings to Rigontec more than 17 years of drug discovery and development experience including leadership roles at Nexigen GmbH, Pfizer and Coley Pharmaceutical Group. Dr. Vollmer will be responsible for leading Rigontec’s R&D efforts and advancing the Company’s RIG-I-based platform focused on discovering and developing treatments for oncological and infectious diseases. He will report to Dr. Christian Schetter, CEO of Rigontec, and will be based in Munich.
“Rigontec has reached a stage of both platform and pipeline development when expanding the leadership to acquire additional industry and scientific experience is extremely important and therefore we are very pleased to welcome Jörg Vollmer to our team,” said Dr. Christian Schetter, CEO of Rigontec. “He has an extensive record of innovative scientific contributions and will bring years of expertise and insight to the Company.”